IN8bio, Inc. (INAB): Price and Financial Metrics
INAB Price/Volume Stats
| Current price | $1.01 | 52-week high | $3.48 |
| Prev. close | $1.01 | 52-week low | $0.65 |
| Day low | $1.00 | Volume | 50,200 |
| Day high | $1.03 | Avg. volume | 288,426 |
| 50-day MA | $1.12 | Dividend yield | N/A |
| 200-day MA | $1.14 | Market Cap | 43.72M |
INAB Stock Price Chart Interactive Chart >
IN8bio, Inc. (INAB) Company Bio
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Latest INAB News From Around the Web
Below are the latest news stories about IN8BIO INC that investors may wish to consider to help them evaluate INAB as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're starting the day with a breakdown of the biggest ones worth watching! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in LeukemiaDurable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including CAR-T.All trial participants remain alive and relapse free as of last assessment, and six patients have been relapse free for over one year.New data shows long-term in-vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration of INB-100, dem |
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private PlacementInitial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations Proceeds to help accelerate advancement of the Company’s gamma-delta T cell therapies NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that it has entered into a securities |
IN8bio Appoints Dr. Corinne Epperly to Board of DirectorsInternationally recognized immuno-oncology and cell therapy executive with 20 years of experience in innovative immunotherapies for solid and hematological cancersBoard-Certified physician-scientist with deep experience at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute (NCI), Goldman Sachs and most recently CARGO Therapeutics NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceuti |
INAB Price Returns
| 1-mo | -7.34% |
| 3-mo | -17.21% |
| 6-mo | -2.88% |
| 1-year | -59.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -26.81% |
| 2023 | -40.26% |
| 2022 | -47.38% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...